Premas Biotech and Oravax to test their vaccine candidate against Omicron
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
Subscribe To Our Newsletter & Stay Updated